

# Antonio G Solimando

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3493707/publications.pdf>

Version: 2024-02-01

92  
papers

2,763  
citations

117625

34  
h-index

214800

47  
g-index

107  
all docs

107  
docs citations

107  
times ranked

3456  
citing authors

#	ARTICLE	IF	CITATIONS
1	Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis. <i>Clinical and Experimental Medicine</i> , 2022, 22, 65-74.	3.6	41
2	Inborn Error of Immunity: A Journey Through Novel Genes and Clinical Presentation. , 2022, , 798-818.		2
3	Highlights in clinical medicine—Giant cell arteritis, polymyalgia rheumatica and Takayasu’s arteritis: pathogenic links and therapeutic implications. <i>Clinical and Experimental Medicine</i> , 2022, 22, 509-518.	3.6	1
4	Junctional adhesion molecule C expression specifies a CD138 <sup>low</sup> /neg multiple myeloma cell population in mice and humans. <i>Blood Advances</i> , 2022, 6, 2195-2206.	5.2	9
5	Exploiting systems biology to investigate the gene modules and drugs in ovarian cancer: A hypothesis based on the weighted gene co-expression network analysis. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112537.	5.6	19
6	Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by expression of lncRNAs. <i>Journal of Pathology</i> , 2022, 256, 402-413.	4.5	15
7	Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection. <i>Pathogens and Global Health</i> , 2022, 116, 297-304.	2.3	7
8	Angiogenesis as Therapeutic Target in Metastatic Prostate Cancer – Narrowing the Gap Between Bench and Bedside. <i>Frontiers in Immunology</i> , 2022, 13, 842038.	4.8	7
9	Identification of Common and Distinct Pathways in Inflammatory Bowel Disease and Colorectal Cancer: A Hypothesis Based on Weighted Gene Co-Expression Network Analysis. <i>Frontiers in Genetics</i> , 2022, 13, 848646.	2.3	6
10	Cardiovascular Risk in Patients With Takayasu Arteritis Directly Correlates With Diastolic Dysfunction and Inflammatory Cell Infiltration in the Vessel Wall: A Clinical, ex vivo and in vitro Analysis. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	4
11	A Challenging Case of Visceral Leishmaniasis. <i>Reports</i> , 2022, 5, 23.	0.5	3
12	Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant. <i>Hematological Oncology</i> , 2022, 40, 987-998.	1.7	5
13	The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring “Multiple Myelomas”. <i>Cancers</i> , 2022, 14, 3271.	3.7	5
14	Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression. <i>Haematologica</i> , 2021, 106, 1943-1956.	3.5	46
15	Effect of thyroidectomy on circulating angiogenic cytokines in papillary thyroid carcinoma and benign goiter: Potential for new biomarkers?. <i>Surgery</i> , 2021, 169, 27-33.	1.9	10
16	BL1391: an established cell line from a human malignant peripheral nerve sheath tumor with unique genomic features. <i>Human Cell</i> , 2021, 34, 238-245.	2.7	4
17	Subgroup-Independent Mapping of Renal Cell Carcinoma—Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries. <i>Frontiers in Oncology</i> , 2021, 11, 621278.	2.8	31
18	Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. <i>Biomedicines</i> , 2021, 9, 373.	3.2	55

#	ARTICLE	IF	CITATIONS
19	Thrombopoietin Promotes Angiogenesis and Disease Progression in Patients with Multiple Myeloma. <i>American Journal of Pathology</i> , 2021, 191, 748-758.	3.8	9
20	The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. <i>Vaccines</i> , 2021, 9, 532.	4.4	65
21	Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine. <i>Cancers</i> , 2021, 13, 2414.	3.7	58
22	Antibiotics or No Antibiotics, That Is the Question: An Update on Efficient and Effective Use of Antibiotics in Dental Practice. <i>Antibiotics</i> , 2021, 10, 550.	3.7	27
23	COVID-19 and the Endocrine System: A Comprehensive Review on the Theme. <i>Journal of Clinical Medicine</i> , 2021, 10, 2920.	2.4	57
24	Identification and monitoring of Copy Number Variants (CNV) in monoclonal gammopathy. <i>Cancer Biology and Therapy</i> , 2021, 22, 404-412.	3.4	4
25	MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease. <i>Cancers</i> , 2021, 13, 3650.	3.7	13
26	Imaging Evaluation of Pulmonary and Non-Ischaemic Cardiovascular Manifestations of COVID-19. <i>Diagnostics</i> , 2021, 11, 1271.	2.6	8
27	The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer. <i>Cancers</i> , 2021, 13, 3433.	3.7	67
28	Prognostic role of neoplastic markers in Takotsubo syndrome. <i>Scientific Reports</i> , 2021, 11, 16548.	3.3	5
29	Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection. <i>Journal of Clinical Medicine</i> , 2021, 10, 3567.	2.4	30
30	A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery. <i>Genes</i> , 2021, 12, 1206.	2.4	35
31	Hepatocellular Cancer. <i>UNIPA Springer Series</i> , 2021, , 689-706.	0.1	2
32	Epstein-Barr Virus in Salivary Samples from Systemic Lupus Erythematosus Patients with Oral Lesions. <i>Journal of Clinical Medicine</i> , 2021, 10, 4995.	2.4	10
33	Worldwide prevalence, genotype distribution and management of hepatitis C. <i>Acta Gastro-Enterologica Belgica</i> , 2021, 84, 633-652.	1.0	10
34	PD-L1 and Notch as novel biomarkers in pancreatic sarcomatoid carcinoma: a pilot study. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 1007-1016.	3.4	13
35	Impact of Antigen Presentation Mechanisms on Immune Response in Autoimmune Hepatitis. <i>Frontiers in Immunology</i> , 2021, 12, 814155.	4.8	11
36	RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS. <i>Haematologica</i> , 2020, 105, 2316-2326.	3.5	12

#	ARTICLE	IF	CITATIONS
37	Early echocardiographic detection of left ventricular diastolic dysfunction in patients with systemic lupus erythematosus asymptomatic for cardiovascular disease. <i>Clinical and Experimental Medicine</i> , 2020, 20, 11-19.	3.6	24
38	<i>cic</i> Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement. <i>Oncologist</i> , 2020, 25, 112-118.	3.7	39
39	New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. <i>Cancers</i> , 2020, 12, 1869.	3.7	41
40	Actors on the Scene: Immune Cells in the Myeloma Niche. <i>Frontiers in Oncology</i> , 2020, 10, 599098.	2.8	51
41	Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling. <i>Cancers</i> , 2020, 12, 3380.	3.7	71
42	Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-7.	1.9	1
43	Telemedicine DSS-AI Multi Level Platform for Monoclonal Gammopathy Assistance. , 2020, , .		6
44	Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study. <i>Life</i> , 2020, 10, 247.	2.4	7
45	Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm. <i>Frontiers in Oncology</i> , 2020, 10, 583781.	2.8	6
46	Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3054.	4.1	41
47	MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3084.	4.1	42
48	Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 95.	8.6	147
49	Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 1594.	2.4	49
50	miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro. <i>Journal of Clinical Medicine</i> , 2020, 9, 670.	2.4	50
51	Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020, 9, 552.	2.4	40
52	Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. <i>Cells</i> , 2020, 9, 167.	4.1	68
53	HB-EGFâ€“EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma. <i>Cancers</i> , 2020, 12, 173.	3.7	28
54	Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department. <i>Frontiers in Medicine</i> , 2020, 7, 625176.	2.6	21

#	ARTICLE	IF	CITATIONS
55	A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche. <i>Journal of Oncology</i> , 2020, 2020, 1-16.	1.3	8
56	Immune system and bone microenvironment: rationale for targeted cancer therapies. <i>Oncotarget</i> , 2020, 11, 480-487.	1.8	45
57	High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2019, 8, 997.	2.4	45
58	Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma Research. <i>Journal of Clinical Medicine</i> , 2019, 8, 999.	2.4	9
59	Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. <i>Cancers</i> , 2019, 11, 942.	3.7	66
60	Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Medicina (Lithuania)</i> , 2019, 55, 698.	2.0	54
61	Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 1972-1976.	0.5	12
62	Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib. <i>Medicina (Lithuania)</i> , 2019, 55, 707.	2.0	53
63	Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview. <i>Cancers</i> , 2019, 11, 1270.	3.7	25
64	CAFs and TGF- $\beta$ 2 Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 330.	3.7	71
65	Long-term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2379-2383.	0.5	7
66	Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies. <i>Medicina (Lithuania)</i> , 2019, 55, 754.	2.0	55
67	Insights into the Regulation of Tumor Angiogenesis by Micro-RNAs. <i>Journal of Clinical Medicine</i> , 2019, 8, 2030.	2.4	61
68	Bone marrow endothelial cells sustain a tumor-specific CD8 <sup>+</sup> T cell subset with suppressive function in myeloma patients. <i>Oncolimmunology</i> , 2019, 8, e1486949.	4.6	58
69	Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes. <i>Journal of Pathology</i> , 2019, 247, 241-253.	4.5	74
70	Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival. <i>Blood</i> , 2019, 134, 855-855.	1.4	7
71	JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. <i>Leukemia</i> , 2018, 32, 736-743.	7.2	55
72	Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma. <i>Annals of Hematology</i> , 2018, 97, 1251-1258.	1.8	13

#	ARTICLE	IF	CITATIONS
73	Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment. <i>Haematologica</i> , 2018, 103, 116-125.	3.5	48
74	Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial. <i>Clinical Immunology</i> , 2018, 191, 110-115.	3.2	62
75	A multiple myeloma that progressed as type I cryoglobulinemia with skin ulcers and foot necrosis. <i>Medicine (United States)</i> , 2018, 97, e12355.	1.0	10
76	Suspected Pericardial Tuberculosis Revealed as an Amyloid Pericardial Mass. <i>Case Reports in Hematology</i> , 2018, 2018, 1-5.	0.4	4
77	Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPIn <sup>®</sup> protein MP0250: a preclinical study. <i>Oncotarget</i> , 2018, 9, 13366-13381.	1.8	37
78	Central Function for JAM-a in Multiple Myeloma Patients with Extramedullary Disease. <i>Blood</i> , 2018, 132, 4455-4455.	1.4	3
79	CIC-Mutation As a Potential Molecular Mechanism of Acquired Resistance to Combined BRAF/MEK Inhibition in CNS Multiple Myeloma. <i>Blood</i> , 2018, 132, 3181-3181.	1.4	3
80	Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma. <i>Oncotarget</i> , 2018, 9, 20563-20577.	1.8	45
81	The small subunit of Hemilipin2, a new heterodimeric phospholipase A2 from <i>Hemiscorpius lepturus</i> scorpion venom, mediates the antiangiogenic effect of the whole protein. <i>Toxicon</i> , 2017, 126, 38-46.	1.6	29
82	Emerging Concepts in Acute Heart Failure: From the Pathophysiology to the Clinical Case Based Approach. <i>International Journal of Critical Care and Emergency Medicine</i> , 2017, 3, .	0.1	0
83	Targeting B-cell non Hodgkin lymphoma: New and old tricks. <i>Leukemia Research</i> , 2016, 42, 93-104.	0.8	51
84	JAM-A as a Prognostic Factor and New Therapeutic Target in Multiple Myeloma. <i>Blood</i> , 2016, 128, 307-307.	1.4	1
85	Microenvironment drug resistance in multiple myeloma: emerging new players. <i>Oncotarget</i> , 2016, 7, 60698-60711.	1.8	137
86	Dyspnea, Fatigue, and Generalized Weakness in a 67-Year-Old Man: Approach to the Patient Between Guidelines and Clinical Judgment. <i>Journal of Cell Science &amp; Therapy</i> , 2016, 07, .	0.3	0
87	A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target. <i>Clinical Cancer Research</i> , 2014, 20, 5796-5807.	7.0	56
88	Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2013, 19, 4371-4382.	7.0	60
89	Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma. <i>Stem Cells International</i> , 2012, 2012, 1-6.	2.5	10
90	Difference in growth hormone response to growth hormone-releasing hormone (GHRH) testing following GHRH subacute treatment in normal aging and growth hormone-deficient adults: Possible perspectives for therapeutic use of GHRH or its analogs in elderly subjects?. <i>Immunopharmacology and Immunotoxicology</i> , 2011, 33, 334-337.	2.4	3

#	ARTICLE	IF	CITATIONS
91	Angiogenesis and Antiangiogenesis in Multiple Myeloma. , 0, , .		1
92	The bone marrow niche landscape: a journey through aging, extrinsic and intrinsic stressors in the haemopoietic milieu. Journal of Cancer Metastasis and Treatment, 0, , .	0.8	4